Department of Surgical Sciences, Urology, Academic Hospital, Uppsala, Sweden.
BJU Int. 2011 May;107(10):1543-5. doi: 10.1111/j.1464-410X.2011.10235.x.
The results for many types of cancers have improved during later decades but not so for bladder cancer. Most patients with muscle-invasive tumors will still succumb to the disease and a high recurrence rate characterises non-muscle invasive tumors.The objective is to critically review the present model of bladder cancer based on newly acquired biological data. The definition of bladder cancer has extended with the introduction of the WHO classification. The corresponding loss of distinction between benign tumor and cancer has not been rewarding and should be reintroduced to facilitate exploration of new molecular findings. The common endpoints recurrence and progression should be redefined or replaced by more appropriate endpoints. The concept of surgery only for locally advanced cancers has proven unsuccessful and has to be complemented with early administered systemic treatment.
在过去几十年中,许多类型的癌症的治疗效果都有所改善,但膀胱癌并非如此。大多数患有肌肉浸润性肿瘤的患者仍将死于该疾病,并且非肌肉浸润性肿瘤的复发率很高。目的是根据新获得的生物学数据,批判性地回顾当前的膀胱癌模型。随着世界卫生组织(WHO)分类的引入,膀胱癌的定义已经扩大。良性肿瘤和癌症之间的区别丧失并没有带来回报,应该重新引入,以促进新的分子发现的探索。复发和进展等常见终点应该重新定义或用更合适的终点替代。只对局部晚期癌症进行手术的概念已被证明是不成功的,必须辅以早期全身治疗。